Research programme: polystyrene microsphere-based cell therapies - Sigilon Therapeutics

Drug Profile

Research programme: polystyrene microsphere-based cell therapies - Sigilon Therapeutics

Alternative Names: Sig 002; Sig-001; Sig-003; Sig-005; Sig-007

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sigilon Therapeutics
  • Class Antihaemorrhagics; Cell therapies
  • Mechanism of Action Cell replacements; Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Blood dyscrasias; Diabetes mellitus; Haemophilia B; Lysosomal-storage diseases

Most Recent Events

  • 08 Mar 2018 Preclinical trials in Haemophilia B in USA (Implant) (9235216; Sigilon Therapeutics Pipeline)
  • 08 Mar 2018 The Committee for Advanced Therapies of the European Medicines Agency grants an Advanced Therapy Medicinal Product designation to Sig 003 for Haemophilia B
  • 01 Nov 2017 Preclinical trials in Blood dyscrasias in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top